Article

Right Heart Pulmonary Circulation Unit Response to Exercise in Patients with Controlled Systemic Arterial Hypertension: Insights from the RIGHT Heart International NETwork (RIGHT-NET)

Olga Vriz 1,2, Paolo Palatini 3, Lawrence Rudski 4, Paolo Frumento 5, Jaroslaw D. Kasprzak 6, Francesco Ferrara 7, Rosangela Cocchia 8, Luna Gargani 9, Karina Wierzbowska-Drabik 6, Valentina Capone 8, Brigid Ranieri 10, Andrea Salzano 10, Anna Agnese Stanziola 10, Albert Maria Marra 12, Roberto Annunziata 8, Salvatore Chianese 8, Salvatore Rega 12, Teresa Saltalamacchia 12, Renato Maramaldi 12, Chiara Sepe 8, Giuseppe Limongelli 13, Filippo Cademartiri 10, Antonello D'Andrea 14, Michele D’Alto 13, Raffaele Izzo 15, Nicola Ferrara 12, Ciro Mauro 9, Antonio Cittadini 12, Grünig Ekkehard 16, Marco Guazzi 12 and Eduardo Bossone 8,16,11 on behalf of the RIGHT Heart International NETwork (RIGHT-NET) Investigators

1 Cardiac Centre, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia; olgavriz@yahoo.com
2 School of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
3 Department of Medicine, University of Padova, 35122 Padova, Italy; palatini@unipd.it
4 Azrieli Heart Center and Center for Pulmonary Vascular Diseases, Jewish General Hospital, McGill University, Montreal, QC H3A 0G4, Canada; lawrence.rudski@mcgill.ca
5 Department of Political Sciences, University of Pisa, 56126 Pisa, Italy; paolo.frumento@unipi.it
6 Department of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland;
kasprzak@ptkardio.pl (I.D.K.); wierzbowska@ptkardio.pl (K.W.-D.)
7 Heart Department, University Hospital of Salerno, 84131 Salerno, Italy; ferrara1975@gmail.com
8 Division of Cardiology, A Cardarelli Hospital, 80131 Naples, Italy; rosangela.cocchia@aocardarelli.it (R.C.);
caponevalentina92@libero.it (V.C.); dr.robertoannunziata@gmail.com (R.A.); sasichian@gmail.com (S.C.);
makida@alice.it (C.S.)
9 Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy; gargani@ifc.cnr.it (L.G.);
ciro.mauro1957@gmail.com (C.M.)
10 IRCCS Synlab SDN, 80143 Naples, Italy; ranieribrigida@gmail.com (B.R.); andre.salzano@gmail.com (A.S.);
cademartirifilippo@gmail.com (F.C.)
11 Department of Respiratory Diseases, Monaldi Hospital, University “Federico II”, 80131 Naples, Italy;
annaagnese.stanziola@unina.it
12 Division of Translational Medical Sciences, “Federico II” University of Naples, 80138 Naples, Italy;
albertomaria.marra@unina.it (A.M.M.); salnog25@gmail.com (S.R.); teresa.saltalamacchia@gmail.com (T.S.);
renatomaramaldi@gmail.com (R.M.); nicola.ferrara@unina.it (N.F.); antonio.cittadini@unina.it (A.C.)
13 Division of Cardiology, Monaldi Hospital, Second University of Naples, 81100 Naples, Italy;
giuseppe.limongelli@unicampania.it (G.L.); mic.dalto@tin.it (M.D.)
14 Department of Cardiology and Intensive Coronary Unit, “Umberto I” Hospital, 84014 Nocera Inferiore, Italy;
antonellodandrea@libero.it
15 Department of Advanced Biomedical Sciences, “Federico II” University of Naples, 80131 Naples, Italy;
raffaele.izzo@unina.it
16 Centre for Pulmonary Hypertension, Thoraklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), 69120 Heidelberg, Germany;
Ekkehard.Gruenig@med.uni-heidelberg.de
17 Heart Failure Unit, Cardiopulmonary Laboratory, University Cardiology Department, IRCCS Policlinico San Donato University Hospital, 20097 Milan, Italy; marco.guazzi@unimi.it
* Correspondence: eduardo.bossone@aocardarelli.it
† Membership of the RIGHT Heart International NETwork (RIGHT-NET) is provided in Acknowledgments.

Abstract: Background. Systemic arterial hypertension (HTN) is the main risk factor for the development of heart failure with preserved ejection fraction (HFpEF). The aim of the study was to assess the trends in PASP, E/E’ and TAPSE during exercise Doppler echocardiography (EDE) in hypertensive (HTN) patients vs. healthy subjects stratified by age. Methods. EDE was performed in 155 hypertensive patients and in 145 healthy subjects (mean age 62 ± 12.0 vs. 54 ± 14.9 years
respectively, \( p < 0.0001 \)). EDE was undertaken on a semi-recumbent cycle ergometer with load increasing by 25 watts every 2 min. Left ventricular (LV) and right ventricular (RV) dimensions, function and hemodynamics were evaluated. Results. Echo-Doppler parameters of LV and RV function were lower, both at rest and at peak exercise in hypertensives, while pulmonary hemodynamics were higher as compared to healthy subjects. The entire cohort was then divided into tertiles of age: at rest, no significant differences were recorded for each age group between hypertensives and normotensives except for \( E/E' \) that was higher in hypertensives. At peak exercise, hypertensives had higher pulmonary artery systolic pressure (PASP) and \( E/E' \) but lower tricuspid annular plane systolic excursion (TAPSE) as age increased, compared to normotensives. Differences in \( E/E' \) and TAPSE between the 2 groups at peak exercise were explained by the interaction between HTN and age even after adjustment for baseline values (\( p < 0.001 \) for \( E/E' \), \( p = 0.011 \) for TAPSE). At peak exercise, the oldest group of hypertensive patients had a mean \( E/E' \) of 13.0, suggesting a significant increase in LV diastolic pressure combined with increased PASP. Conclusion. Age and HTN have a synergic negative effect on \( E/E' \) and TAPSE at peak exercise in hypertensive subjects.

Keywords: echocardiography stress test; pulmonary pressure; left ventricular diastolic dysfunction

1. Introduction

Systemic arterial hypertension (HTN) is the most common cardiovascular (CV) risk factor among patients affected by heart failure with preserved ejection fraction (HFpEF) [1,2]. In this regard, left ventricular hypertrophy (LVH) along with abnormal left ventricular (LV) relaxation and left atrial enlargement represents the characteristic “pathologic triad” usually detected by transthoracic Doppler echocardiography (TTE) in hypertensive patients as a direct consequence of the chronically increased LV workload [3,4]. However, it should be noted, in mild-moderate HTN, LV filling pressure and related pulmonary arterial systolic pressure (PASP) may be normal at rest but may show an abnormal and disproportionate increase during exercise [5,6]. From the clinical point of view, an increase in LV filling pressure and PASP during physical activities might explain the dyspnea in those hypertensive patients with well controlled resting blood pressure (BP) and with no signs of HFpEF [5,6].

The aim of the study was to assess the trends in PASP, \( E/E' \) and TAPSE during exercise Doppler echocardiography (EDE) in hypertensive patients vs. healthy subjects stratified by age.

2. Methods

2.1. Study Population

One hundred and fifty-five consecutive patients with idiopathic uncomplicated mild-to-moderate HTN and one hundred and forty-five healthy subjects were enrolled by 13 RIGHT-NET participating centers [7,8]. Healthy subjects were recruited, as previously reported, among volunteers without structural heart disease on TTE and/or history of any cardiovascular disease and/or any systemic diseases known to affect the cardiovascular system [7–11]. Patients were defined to be hypertensive if office systolic blood pressure (SBP) values were \( \geq 140 \) mmHg and/or diastolic blood pressure (DBP) values were \( \geq 90 \) mmHg on three consecutive visits or if they were on anti-hypertensive therapy [4]. Office brachial BP and heart rate (HR) were measured twice in supine position, in the right arm, 10 min apart in a quiet room. All participants underwent full screening for CV disease, including an interview on medical history, use of medications, and lifestyle habits (alcohol intake, smoking, physical activity) [12]. Physical examinations (height, weight, HR and BP) and clinical assessments were conducted according to standardized protocols by trained and certified staff [7,10]. Body surface area (BSA) was calculated according to the DuBois formula (\( 0.20247 \times \text{height (m)}^{0.725} \times \text{weight (kg)}^{0.425} \)).
2.2. Resting Echocardiographic Doppler Examination

TTE examinations were performed at rest with commercially available equipment on all subjects, according to standardized protocols [7]. All echo-Doppler measurements were obtained according to current American Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging (EACVI) recommendations [13–15]. In particular, peak tricuspid regurgitation velocity (TRV) was measured from multiple views (the spectral profile of the TR jet in the RV inflow projection of the parasternal long-axis view, the parasternal short-axis view or the apical 4-chamber view); the highest TRV was used for calculation of RV systolic pressure. The PASP estimation was based on the simplified Bernoulli equation applied to TRV with the addition of estimated right atrial pressure (RAP) based on inferior vena cava (IVC) size and collapse: 5 mmHg was added in all subjects showing IVC < 21 mm diameter and >50% collapsibility to the systolic transtricuspid gradient (PASP = 4 V^2 + RAP, where V = maximal velocity of tricuspid regurgitation jet) [16]. PASP was assumed to be equal to the RV systolic pressure in the absence of pulmonic stenosis and/or right ventricular outflow tract obstruction. An agitated saline solution was used in cases of poor TRV Doppler signal, such as in the presence of incomplete spectral wave envelope and/or artifacts. Mean pulmonary artery pressure (mPAP) was calculated as 0.6 × PASP + 2 [17]. TAPSE was measured from the 4 chamber views by placing an M-mode cursor through the tricuspid annulus measuring the excursion distance between end-diastole and end-systole (in mm) and with optimal image orientation and alignment to avoid underestimation. The TAPSE/PASP ratio was then estimated [18]. Tissue Doppler velocities (TDI) of the tricuspid annulus were recorded from the apical four-chamber view, by placing the sample volume at the level of lateral corner of the tricuspid annulus, adjusting the spectral pulsed Doppler signal filters within Nyquist limit of 15–20 cm/s, and using the minimal sufficient gain setting to avoid signal blurring.

2.3. Exercise Doppler Echocardiography Examination

EDE was performed according to the current recommendations on a semi-recumbent cycle ergometer with an incremental workload of 25 watts every 2 min up to the symptom-limited maximal tolerated workload [7,19,20]. The exercise table was tilted laterally by 20 to 30° to the left. HR (by ECG lead) was continuously monitored, and BP (by sphygmomanometer) was measured at baseline and during the last 15 s of each workload step [7]. Key echocardiographic measurements were acquired at baseline and peak exercise, including left and right ventricular function, valvular gradients, regurgitant flows, left and right heart Doppler derived hemodynamics [PASP, mPAP, pulmonary vascular resistance (PVR), right atrial pressure (RAP) and E/E' and cardiac output (CO)] [7]. LV diastolic parameters E and A peak velocities (m/sec), their ratio and E wave deceleration time (ms), were measured during low level of exercise (heart rate < 110 bpm). The early (e') diastolic velocities were measured by TDI at the septal and lateral corner of the mitral annulus and the mean between the two values was calculated. Mitral E velocity, corrected for the influence of relaxation (i.e., the E/mean e' ratio), was assessed to estimate LV filling pressures [7].

2.4. Image Analysis and Quality Control

All participating centers were chosen according to recommended standard operational procedures in terms of data imaging acquisition (operational modes, machine settings), data storage (data format, transfer procedure) and data processing (software used and measurement procedures). Echocardiographic recordings—both at rest and exercise—were reviewed and analyzed offline at each center by a certified operator expert in TTE. A quality control procedure was set to reduce variability among laboratories and operators and to maintain and improve the quality of subsequent collections of data according to the American and European Recommendations and Guidelines [8,9,13,19,20]. In addition, the feasibility of semi-recumbent bicycle EDE for the assessment of right heart-pulmonary cir-
calculation function and hemodynamic indices among healthy individuals and patients at risk of developing pulmonary hypertension (PH) was also previously tested and reported [9].

3. Statistical Analysis

Data were expressed as mean ± standard deviation and each relative frequency of feasibility into a percentage. Normal distribution of the continuous variables was assessed by the Kolmogorov-Smirnov test. T-test for unpaired observations was used to compare the differences between normal and hypertensive subjects. Differences between normotensive and hypertensive were adjusted by age, sex and BSA. The entire cohort was divided into tertiles of age: group 1, younger than 51 years, group 2, between 51 and 66 years and group 3, older than 66 years. ANOVA was used to compare continuous variables within the groups. Differences were adjusted for confounding factors (sex, BSA, therapy). The chi-squared test was applied to compare categorical variables. A mixed model with estimation method REML was applied to test the effect of age, hypertension state and their interaction adjusted by sex, therapy and corresponding variables at baseline, on the dependent variables at peak exercise. Non-parametric tests were used when assumptions of normality tests were not met. \( p \) values < 0.05 were considered statistically significant. Data analysis was performed using SPSS (Rel. 11.0, 2002, SPSS Inc., Chicago, IL, USA).

Ethical Considerations

The study protocol followed the principles of the Declaration of Helsinki and each participating center had obtained both approval from its local research ethics committee and informed consent from each subject. Clinical trials Gov Identifier: NCT03041337.

4. Results

Hypertensive patients (78% on antihypertensive therapy) were older (62 ± 12 vs. 54 ± 14.9 years, \( p < 0.0001 \)) and heavier (BMI 27.8 ± 4 vs. 26 ± 3.5 kg/m\(^2\), \( p < 0.0001 \)) and were less frequently females (27% vs. 40%, \( p < 0.01 \)) as compared to normotensive subjects (Table 1).

Table 1. General characteristics in normal and hypertensive subjects.

|                    | Normotensive \( n = 145 \) | Hypertensive \( n = 155 \) | \( t \)-Test | ANOVA Adjusted by Age, Sex, BSA |
|--------------------|-----------------------------|-----------------------------|-------------|--------------------------------|
| Age (years)        | 54 ± 14.9                   | 62 ± 12.0                   | 0.0001      | -                              |
| M/F                | 65/58                       | 113/42                      | 0.01        | -                              |
| BMI (Kg/m\(^2\))   | 26 ± 3.5                    | 27.8 ± 4                    | 0.0001      | -                              |
| BSA (m\(^2\))      | 1.97 ± 0.1                  | 1.89 ± 0.2                  | 0.0001      |                                |
| SBP (mmHg)         | 123 ± 16                    | 137 ± 20                    | 0.0001      | 0.0001                         |
| DBP (mmHg)         | 77 ± 10                     | 82 ± 11                     | 0.0001      | 0.0001                         |
| HR (bpm)           | 75 ± 15                     | 73 ± 13                     | 0.1         | 0.7                            |
| Hemoglobin (dL/L)  | 14.6 ± 1.8                  | 14.4 ± 1.7                  | 0.3         | 0.0001                         |
| Creatinine (mg/dL) | 0.97 ± 0.18                 | 1.0 ± 0.22                  | 0.2         | 0.9                            |
| Glucose (mg/dL)    | 110 ± 48                    | 117 ± 40                    | 0.4         | 0.039                          |
| Tot Chol (mg/dL)   | 198 ± 38                    | 177 ± 52                    | 0.07        | 0.002                          |
| HDL (mg/dL)        | 52 ± 13                     | 49 ± 12                     | 0.3         | 0.001                          |
| Triglycerides (mg/dL) | 117 ± 70          | 119 ± 62                    | 0.9         | 0.006                          |

Abbreviations: BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; HR, heart rate; M/F, Male/Female; SBP, systolic blood pressure.
Furthermore, after adjustment for age, sex and BSA, hypertensives have increased LV dimension with LV remodeling, increased PASP, PASP/CI and PVR, higher E/A and E/E', lower TAPSE/PASP but similar cardiac output (CO) and TAPSE (Table 2).

**Table 2.** Baseline echocardiographic variables in normotensive and hypertensive subjects.

|                  | Normotensive n = 145 | Hypertensive n = 155 | t-Test | ANOVA Adjusted by Age, Sex, BSA |
|------------------|----------------------|----------------------|--------|-------------------------------|
| LVDD (mm)        | 47.0 ± 3.9           | 48.0 ± 7.0           | 0.1    | 0.0001                        |
| IVSD (mm)        | 9.7 ± 1.2            | 10.0 ± 2.0           | 0.0001 | 0.0001                        |
| PWTD (mm)        | 9.2 ± 1.3            | 9.2 ± 1.7            | 0.4    | 0.0001                        |
| LVM (gr)         | 153.0 ± 36           | 174.8 ± 69           | 0.001  | 0.0001                        |
| LVMI (gr/m²)     | 81.9 ± 17            | 91.8 ± 31            | 0.001  | 0.015                         |
| RWT              | 0.35 ± 0.08          | 0.39 ± 0.09          | 0.0001 | 0.0001                        |
| LVEF (%)         | 64.0 ± 7.0           | 63.0 ± 9.0           | 0.1    | 0.023                         |
| LAVi (vol/BSA)   | 22.8 ± 8             | 26.1 ± 11.7          | 0.01   | 0.0001                        |
| E/A              | 1.20 ± 0.5           | 1.17 ± 0.5           | 0.2    | 0.0001                        |
| E/E'             | 7.3 ± 2.5            | 8.8 ± 3.2            | 0.0001 | 0.0001                        |
| SV (mL)          | 69.7 ± 16            | 71.0 ± 20            | 0.6    | 0.003                         |
| CO (mL/min)      | 5.1 ± 1.4            | 5.1 ± 1.7            | 0.7    | 0.001                         |
| CI (mL/min/m²)   | 2.8 ± 0.8            | 2.7 ± 0.8            | 0.4    | 0.27 (*)                      |
| TAPSE (mm)       | 23.0 ± 3.0           | 23.0 ± 3.7           | 0.9    | 0.1                           |
| PASP (mmHg)      | 22.0 ± 3.0           | 25.0 ± 7.0           | 0.0001 | 0.0001                        |
| mPAP (mmHg)      | 15.4 ± 3.1           | 17.2 ± 4.2           | 0.0001 | 0.0001                        |
| PASP/CI          | 4.7 ± 2.2            | 10.2 ± 4.3           | 0.0001 | 0.0001 (*)                    |
| TAPSE/PASP       | 1.2 ± 0.4            | 1.06 ± 0.3           | 0.04   | 0.0001                        |
| RVOT-AccTime (ms)| 143 ± 27             | 127 ± 26             | 0.0001 | 0.0001                        |
| PVR (WU)         | 1.27 ± 0.4           | 1.6 ± 0.6            | 0.0001 | 0.008                         |

Abbreviations: CI, left ventricular cardiac output index; CO, left ventricular cardiac output; AccTime, acceleration time; E/A, transmitral flow ratio; E/E', E wave and E' wave on TDI ratio; IVSD, interventricular septum in systole; LAVi, left atrial volume index; LV, left ventricular mass; LVEF, left ventricular ejection fraction; LVDD, left ventricular internal diameter in diastole; LVM, left ventricular mass; LVMI, left ventricular mass index; mPAP, mean pulmonary artery pressure; PASP, pulmonary arterial systolic pressure; PVR, pulmonary vascular resistances; PWTD, posterior wall thickness in diastole; RVOT-AccTime, acceleration time on RVOT (right ventricular outflow tract); RWT, relative wall thickness; SV, left ventricular stroke volume; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion / pulmonary systolic arterial. (*) no BSA.

### 4.1. Exercise Doppler Echocardiography

Hypertensives exercised for a shorter period of time, reached lower peak workload, SBP and HR compared to normotensive healthy subjects even after adjustment for age, sex and BSA. They also reached lower LVEF, SV and CO but higher E/E'. In addition, PASP, PASP corrected by flow (PASP/CI), mPAP and PVR were higher, while TAPSE and TAPSE/PASP were lower in hypertensives (Table 3).

### 4.2. Analysis by Tertiles of Age

The entire cohort was divided into tertiles of age. In hypertensives, group 1 included 28 patients (mean age 48 ± 8 years), group 2 included 65 patients (mean age 59.6 ± 4.4 years) and group 3 included 62 patients (mean age 73.5 ± 4.4 years). In normotensives, group 1 included 62 subjects (mean age 40.1 ± 9 years), group 2 included 43 subjects (mean age 58 ± 4.5 years) and group 3 included 38 subjects (mean age 72 ± 3.5 years). Age was similar
between hypertensive and normotensives within each age group, percentage of males was higher in hypertensives, and BSA was lower in the elderly group of hypertensives (Table 3). Details of general and echocardiographic characteristics at baseline and peak exercise of the hypertensive cohort divided in tertiles of age are reported in Tables 4–6. Briefly, baseline echocardiographic data underlined a progressive increase in IVS thickness in diastole according to increase in age and a significant increase in E/E' as expression of increase of LV end diastolic pressure (LVED). TAPSE was slightly, although significantly, decreasing with age increase. At peak exercise, along with age group increase, the amount of work/exercise time, HR response, LVEF and SV decreased. In addition, TAPSE and TAPSE/PASP decreased, while PASP and also PASP corrected by flow (PASP/CI) increased.

Table 3. Difference between normotensive and hypertensive subjects at peak stress test.

|                      | Normotensive n = 145 | Hypertensive n = 155 | t-Test  | ANOVA Adjusted by Age, Sex, BSA |
|----------------------|----------------------|----------------------|---------|----------------------------------|
| Watts (peak)         | 133 ± 38             | 104 ± 35             | 0.0001  | 0.0001                           |
| Time Exe (min)       | 10.4 ± 3.0           | 8.4 ± 2.8            | 0.0001  | 0.0001                           |
| SBP (mmHg)           | 188 ± 29             | 165 ± 24             | 0.0001  | 0.0001                           |
| DBP (mmHg)           | 96 ± 17              | 91 ± 13              | 0.047   | 0.02                             |
| HR (bpm)             | 138 ± 18             | 123 ± 19             | 0.0001  | 0.0001                           |
| LVEF (%)             | 71 ± 8.1             | 69 ± 11              | 0.09    | 0.0001                           |
| E/E'                 | 6.6 ± 2.9            | 10.7 ± 5.5           | 0.0001  | 0.0001                           |
| SV (mL)              | 89 ± 20              | 86 ± 26              | 0.1     | 0.007                            |
| CO peak-rest (mL/min)| 7.2 ± 2.8            | 5.2 ± 3.5            | 0.0001  | 0.0001                           |
| CO (mL/min)          | 12.5 ± 3.1           | 10.6 ± 3.6           | 0.0001  | 0.0001                           |
| CI (mL/min/m²)       | 6.6 ± 1.7            | 5.6 ± 1.8            | 0.0001  | 0.0001 (*)                       |
| TAPSE (mm)           | 28.3 ± 3.4           | 28.4 ± 5.2           | 0.7     | 0.0001                           |
| PASP (mmHg)          | 35.4 ± 9.4           | 47.3 ± 13.9          | 0.0001  | 0.0001                           |
| PASP peak-rest       | 13.6 ± 9.1           | 22.7 ± 13.7          | 0.0001  | 0.0001                           |
| mPAP (mmHg)          | 23 ± 5.8             | 31 ± 8.5             | 0.0001  | 0.0001                           |
| PASP/W               | 3.1 ± 1.4            | 5.1 ± 2.4            | 0.0001  | 0.0001                           |
| PASP/CI              | 5.8 ± 3.4            | 9.4 ± 4.6            | 0.0001  | 0.0001 (*)                       |
| TAPSE/PASP (mm/mmHg) | 0.94 ± 0.2           | 0.65 ± 0.2           | 0.0001  | 0.0001                           |
| RVOT-AccTime (ms)    | 142.8 ± 33           | 116 ± 24             | 0.0001  | 0.0001                           |
| PVR (WU)             | 1.38 ± 0.5           | 1.74 ± 0.5           | 0.0001  | 0.0001                           |

(*) no BSA.

Table 4. Hypertensive patient characteristics divided by age.

|                      | Group 1 <51 Years n = 28 | Group 2 >51 and <66 Years n = 65 | Group 3 >66 Years n = 62 | ANOVA | ANOVA Adjusted by Age, Sex, BSA |
|----------------------|--------------------------|----------------------------------|--------------------------|-------|----------------------------------|
| LVIDD (mm)           | 47.0 ± 3.9               | 48.0 ± 7.0                       | 73.5 ± 4.4               | 0.1   | 0.0001                           |
| Age (years)          | 43 ± 8                   | 59.6 ± 4.4                       | 73.5 ± 4.4               | 0.0001| -                                |
| M/F                  | 24/4                     | 48/17                            | 41/21                    | 0.1   | -                                |
| BMI                  | 27 ± 5                   | 28.4 ± 4                         | 27 ± 3.8                 | 0.2   | -                                |
Table 4. Cont.

| Group 1 <51 Years n = 28 | Group 2 >51 and <66 Years n = 65 | Group 3 ≥66 Years n = 62 | ANOVA | ANOVA Adjusted by Age, Sex, BSA |
|--------------------------|-------------------------------|--------------------------|-------|----------------------------------|
| BSA (m²) | 1.95 ± 0.2 | 1.9 ± 0.2 | 1.83 ± 0.2 | 0.004 | - |
| SBP (mmHg) | 142 ± 22 | 136 ± 21 | 136 ± 18 | 0.3 | 0.0001 |
| DBP (mmHg) | 87.9 ± 13 | 83 ± 12 | 78.4 ± 8 | 0.002 | 0.0001 |
| HR (bpm) | 69.9 ± 13 | 74 ± 12 | 73 ± 13 | 0.4 | 0.002 |
| Therapy (no/yes) | 15/13 | 15/50 | 4/58 | 0.0001 | 0.0001 (*) |
| Hemoglobin (dL/L) | 15 ± 1.7 | 14.4 ± 1.4 | 13.8 ± 1.9 | 0.02 | 0.0001 |
| Creatinine (mg/dL) | 0.98 ± 0.17 | 1.01 ± 0.19 | 1 ± 0.3 | 0.8 | 0.5 |
| Glucose (mg/dL) | 102 ± 22 | 124 ± 46 | 120 ± 41 | 0.1 | 0.11 |
| Tot Chol (mg/dL) | 190 ± 45 | 173 ± 62 | 157 ± 47 | 0.08 | 0.09 |
| HDL (mg/dL) | 51 ± 11 | 49 ± 11 | 50 ± 13 | 0.5 | 0.6 |
| Triglycerides (mg/dL) | 104 ± 59 | 137 ± 68 | 102 ± 49 | 0.6 | 0.018 |

Abbreviations: M/F, male/female; BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure. No adjusted by therapy (*).

Table 5. Baseline echocardiographic characteristics in hypertensive patients divided into 3 groups of age.

| Group 1 ≤51 Years n = 28 | Group 2 >51 and <66 Years n = 65 | Group 3 ≥66 Years n = 61 | ANOVA | ANOVA Adj by Sex BSA, Therapy |
|--------------------------|-------------------------------|--------------------------|-------|----------------------------------|
| LVIDD (mm) | 49 ± 4.7 | 48 ± 8.5 | 47 ± 6.4 | 0.3 | 0.1 |
| IVSD (mm) | 9.6 ± 2.0 | 10.4 ± 2.3 | 10.8 ± 1.7 | 0.036 | 0.025 |
| PWTD (mm) | 9.4 ± 2 | 9.1 ± 1.7 | 9.3 ± 1.5 | 0.1 | 0.9 |
| LVM (gr) | 176 ± 44 | 177 ± 89 | 171 ± 55 | 0.2 | 0.09 |
| LVMI (gr/m²) | 89 ± 20 | 91 ± 40 | 93 ± 25 | 0.1 | 0.1 (*) |
| RWT | 0.39 ± 0.01 | 0.39 ± 0.1 | 0.40 ± 0.09 | 0.6 | 0.3 |
| LVEF (%) | 62 ± 8.5 | 64 ± 8 | 61 ± 9 | 0.07 | 0.6 |
| LAVi (vol/BSA) | 21 ± 5.6 | 23.6 ± 9.9 | 29.4 ± 13 | 0.006 | 0.9 (*) |
| E/A | 1.5 ± 0.7 | 1.2 ± 0.3 | 1.03 ± 0.3 | 0.00001 | 0.1 |
| E/E' | 6.7 ± 2.2 | 8.5 ± 3.2 | 10 ± 2.9 | 0.00001 | 0.0001 |
| SV (mL) | 69 ± 18 | 73 ± 23 | 69 ± 18 | 0.001 | 0.001 |
| CO (L/min) | 4.8 ± 1.5 | 5.4 ± 1.7 | 5.0 ± 1.7 | 0.8 | 0.03 |
| CI (mL/min/m²) | 2.5 ± 0.8 | 2.7 ± 0.8 | 2.7 ± 0.9 | 0.5 | 0.2 (*) |
| TAPSE (mm) | 23.5 ± 3.7 | 23 ± 3.2 | 23 ± 4.2 | 0.7 | 0.001 |
| mPAP (mmHg) | 22.2 ± 5.9 | 24.2 ± 5.7 | 26.6 ± 8.1 | 0.017 | 0.7 |
| PASP/Ci | 5.9 ± 3.4 | 17.8 ± 3.7 | 17.6 ± 5 | 0.036 | 0.28 |
| TAPSE/PAP (mm/mHg) | 9.7 ± 3.2 | 9.7 ± 3.9 | 10.9 ± 5.0 | 0.4 | 0.7 (*) |
| RVOT-AccTime (ms) | 132 ± 23 | 127 ± 24 | 124 ± 26 | 0.09 | 0.2 |
| PVR (WU) | 1.61 ± 0.6 | 1.6 ± 0.5 | 1.6 ± 0.6 | 0.8 | 0.4 |

Abbreviations: AccTime, acceleration time; CI, left ventricular cardiac output index; CO, left ventricular cardiac output; E/A, transmitral flow ratio; E/E', E wave and E' wave on TDI ratio; IVSD, interventricular septum in systole; LAVi, left atrial volume index; LVEF, left ventricular ejection fraction; LVIDD, left ventricular internal diameter in diastole; LV, left ventricular mass; LVMI, left ventricular mass index; mPAP, mean pulmonary artery pressure; PASP, pulmonary arterial systolic pressure; PWTD, posterior wall thickness in diastole; RWT, relative wall thickness; PVPR, pulmonary vascular resistances; RVOT-AccTime, acceleration time on RVOT (right ventricular outflow tract); SV, left ventricular stroke volume; TAPSE, tricuspid annular systolic excursion; TAPSE/PAP, tricuspid annular systolic excursion/pulmonary systolic arterial. (*) no BSA.
Table 6. Hypertensive patient characteristics at peak stress divided by age.

| Group 1 ≤51 Years | Group 2 >51 and <66 | Group 3 ≥66 Years | ANOVA | ANOVA Adj by Sex, BSA, Therapy |
|-------------------|---------------------|-------------------|-------|-----------------------------|
| Watts (peak)      | 120 ± 33            | 100 ± 32          | 93 ± 35 | 0.0001 | 0.001 |
| Time Exe (min)    | 5.2 ± 1.2           | 4.3 ± 1.3         | 3.6 ± 1.3 | 0.0001 | 0.001 |
| SBP (mmHg)        | 175 ± 28            | 169 ± 27          | 158 ± 19 | 0.1 | 0.2 |
| DBP (mmHg)        | 104 ± 15            | 95 ± 14           | 84 ± 8   | 0.0001 | 0.5 |
| HR (bpm)          | 133 ± 16            | 127.3 ± 16        | 113 ± 19 | 0.0001 | 0.001 |
| LVEF (%)          | 74 ± 9.5            | 69 ± 10           | 65 ± 12  | 0.01 | 0.001 |
| E/E'              | 7.5 ± 2.0           | 9.7 ± 6.0         | 13.0 ± 4.6 | 0.005 | 0.0001 |
| SV (mL)           | 89.0 ± 29.0         | 88.7 ± 25.0       | 82.0 ± 27.0 | 0.4 | 0.0001 |
| CO peak-rest      | 7.1 ± 3.8           | 5.5 ± 3.0         | 4.4 ± 3.3 | 0.005 | 0.0001 |
| CO (L/min)        | 12.0 ± 3.5          | 11.3 ± 3.4        | 9.3 ± 3.5 | 0.0001 | 0.0001 |
| CI (L/min/m2)     | 6.1 ± 1.7           | 5.8 ± 1.7         | 5.5 ± 1.7 | 0.007 | 0.0001 (*) |
| TAPSE (mm)        | 32 ± 5.3            | 28 ± 4.8          | 27 ± 4.8 | 0.0001 | 0.0001 |
| PASP (mmHg)       | 51 ± 16             | 43 ± 13           | 49 ± 12  | 0.01 | 0.0001 |
| PASP/CI           | 8.1 ± 2.9           | 7.9 ± 3.9         | 11.1 ± 5.0 | 0.001 | 0.016 |
| mPAP (mmHg)       | 34 ± 10.0           | 28 ± 8.0          | 32 ± 7.1 | 0.006 | 0.0001 |
| TAPSE/PASP (mm/mmHg) | 0.66 ± 0.2     | 0.71 ± 0.2        | 0.56 ± 0.2 | 0.0001 | 0.059 |
| AccTime (ms)      | 127 ± 24            | 118 ± 20          | 110 ± 2  | 0.04 | 0.003 |
| PVR (WU)          | 1.73 ± 0.5          | 1.70 ± 0.5        | 1.79 ± 0.5 | 0.8 | 0.2 |

Abbreviations: AccTime, acceleration time; CI, left ventricular cardiac output index; CO, left ventricular cardiac output; E/E’, E wave and E’ wave on TDI ratio; LVEF, left ventricular ejection fraction; LV left ventricular mass; mPAP, mean pulmonary artery pressure; PASP, pulmonary arterial systolic pressure; PVR, pulmonary vascular resistances; RVOT-AccTime, acceleration time on RVOT (right ventricular outflow tract); SV, left ventricular stroke volume; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion/pulmonary systolic arterial. (*) no BSA.

As reported in Table 7, the effect of increase in age combined with the hypertensive state, adjusted by confounders, such as sex, therapy and the corresponding variable at baseline, was responsible for the significant increase in E/E’ and decreased in TAPSE (Supplementary Table S1) meaning that exercise was able to unmask an abnormal increase in LVED pressure and decrease RV longitudinal contraction in hypertensives. No effect of this combination was observed for PASP, TAPSE/PASP or CO.

Table 7. Evaluation of hemodynamic parameters at peak exercise tested by mixed model.

| Fixed Factors | Adjustment | p Value |
|---------------|------------|---------|
| E/E' PEAK exercise | Hypertensive status | Gender | 0.2 |
| Age | Therapy | 0.7 |
| Hypertensive status * | Age | E/E’ at baseline | 0.0001 |
| TAPSE PEAK | Hypertensive status | Gender | 0.0001 |
| Age | Therapy | 0.8 |
| Hypertensive status * | Age | TAPSE at baseline | 0.007 |
| PASP PEAK | Hypertensive status | Gender | 0.0001 |
| Age | Therapy | 0.002 |
| Hypertensive status * | Age | PASP at baseline | 0.15 |
Table 7. Cont.

| Fixed Factors | Adjustment | p Value |
|---------------|------------|---------|
| TAPSE/PASP PEAK | Hypertensive status | Gender | 0.0001 |
| Age | Therapy | 0.014 |
| Hypertensive status * Age | TAPSE/PASP baseline | 0.66 |
| CO PEAK | Hypertensive status | Gender | 0.6 |
| Age | Therapy | 0.012 |
| Hypertensive status * Age | CO at baseline | 0.53 |

Abbreviations: CO, left ventricular cardiac output; PASP, pulmonary arterial systolic pressure; TAPSE, tricuspid annular systolic excursion; TAPSE/PASP, tricuspid annular systolic excursion/ pulmonary arterial systolic pressure. * = interaction (hypertensive state and age).

5. Discussion

Echocardiography is an established, user-friendly, low cost, radiation-free imaging technique that can provide abundant information on the structure and function of the heart at rest as well as on exercise. EDE is commonly used in different settings, such as ischemic heart disease [21], valvular heart disease [22] and chronic heart failure [23], including patients with HfPfEF who presented with heart failure symptoms during exercise and are characterized as having ‘borderline’ LV diastolic dysfunction [23,24]. Indeed, exercise echocardiography may help rule out HfPfEF adding exercise E/e’ data [23,25].

It should be also noted that the additional simultaneous assessment of right heart pulmonary circulation unit function and hemodynamic responses to dynamic exercise may have several clinical diagnostic and prognostic implications [26–32]. Argiento et al. demonstrated the usefulness of EDE for studying the pulmonary circulation among healthy subjects providing realistic values compared to those obtained by invasive hemodynamic measurements [33,34]. Bossone et al. showed that athletes have higher TRV compared with healthy control subjects both at rest and during exercise related to the higher SV and CO reached [35]. Interestingly, Forton et al., in a cohort of adolescents and adults who underwent EDE, found that pulmonary vascular distensibility coefficient α was inversely related to age at rest as well as during exercise [36]. These results confirm the age-related increase in pulmonary artery pressure (positive correlation) [37–39].

Exercise Doppler Echocardiography in Systemic Arterial Hypertension

As far as we know, there are few studies on EDE in systemic hypertensive patients focusing on the right heart hemodynamics. Vriz et al. [40] studied 25 young, uncomplicated, never treated hypertensive patients at baseline and during bicycle stress test matched for age and sex with a group of healthy subjects The hypertensives had significantly higher mPAP and lower CI values at baseline and at peak exercise compared to healthy subjects, but similar α-index (index of distensibility).

In the present study, when the group of normotensives and hypertensives were divided in tertiles of age, E/E’ ratio, TAPSE, PASP, TAPSE/PASP and CO were similar within the same age group at rest. At peak exercise, on the other hand, there was a significant increase in E/E’ and decrease in TAPSE in hypertensives across age groups, while no significant changes in the normotensive groups were observed. PASP was constantly higher in hypertensives at peak exercise compared to the groups of normotensives.

Echocardiography estimation of E/E’, which is less age-dependent than e’ [41] and is strongly influenced by severity of LVH [42], has been proven to have diagnostic value during exercise [24,25]. Estimation of E/E’ is also reported to have a good correlation with pulmonary capillary wedge pressure (PCWP) at rest and sufficient capacity to predict exercise-induced elevation of PCWP [5,6,43]. In this regard, E/E’ higher than 13 during exercise has been found to have a sensitivity and specificity of 73% and 96% for detecting...
increased LV diastolic pressure [5]. Moreover, the increase in E/E’ during exercise has a good sensitivity/specificity for prediction of reduced exercise capacity and survival [5,44]. In particular, Shim et al. provided data on the prognostic values of the increase in pulmonary pressure during exercise, but the excessive risk was restricted only to the subjects with combined increase in E/E’ during stress test [45]. In the present study, however, at peak exercise, the oldest group of hypertensive patients had a mean E/E’ of 13, suggesting significant increase in LV diastolic pressure combined with increased PASP.

It should also be highlighted that TAPSE showed, during exercise, a different trend in normal subjects vs. hypertensive ones with a significant progressive decrease as age increased in the later groups. Thus, impaired TAPSE at peak exercise could represent RV-PA uncoupling in hypertensives. In addition, a progressive decrease in TAPSE/PASP as age increased was observed [46].

6. Study Limitations

A few limitations of the current study need to be highlighted. Firstly, not all the variables of RV function were considered, such as fractional area change and strain of the RV. As pertains to RV strain, when the multicenter study was started, few centers had echomachines implemented with strain software and even fewer had a vendor-independent software for 2D strain reading. Nevertheless, the parameters included have been well validated in the context of RV function in the setting of increased afterload, with exercise and in the evaluation of RV-PA coupling. Second, we had a relatively smaller number of healthy elderly subjects that underwent stress testing; however, this number is still substantial when compared with the existing literature. Third, E/e’ ratio may be not accurate for the estimation of LV filling pressures in normal subjects, patients with heavy annular calcification, mitral valve and pericardial disease and coronary artery disease (sampled segments dysfunction). Furthermore, normal cutoff values may vary depending on the measurement site used. In this regard, it should be underlined there is the so called “E/e’ ratio gray zone” in which LV filling pressures are indeterminate [15]. Finally, stress invasive hemodynamic tests (gold standard) were not included in the RIGHT-NET [7].

7. Conclusions

Hypertensive patients are a heterogeneous group that might require additional investigations to understand the impact of HTN on their disease state. In the present study, at rest, no significant differences in hemodynamics were seen between hypertensive patients and healthy subjects among age groups and, as a consequence, LV filling pressure values were far away from the condition of HFpEF. However, EDE unmasked an evident different trend in LV filling pressure and TAPSE among hypertensive ones. Furthermore, in the elderly hypertensive cohort, the significant increase in LV filling pressure could be partially responsible for the increase in PASP, while the decrease in TAPSE may be a significant marker of RV-PV uncoupling. In summary, age and hypertension have a negative synergic effect on surrogate echocardiographic parameters of LV filling pressure and RV contractility. Further prospective longitudinal studies are needed in order to clearly define a “pre-HFpEF phenotype” along with potential therapeutic interventions.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11020451/s1, Table S1: Trend of hemodynamic parameters at baseline and at peak exercise in normotensive and hypertensive subjects.

Author Contributions: All authors have contributed to the work. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study protocol followed the principles of the Declaration of Helsinki and each participating center had obtained both approval from its local research ethics committee. Clinical trials Gov Identifier: NCT03041337.
**Informed Consent Statement:** Informed consent from each subject had obtained.

**Data Availability Statement:** The data that support the findings of this review are openly available in the References section.

**Acknowledgments:** The RIGHT Heart International NETwork (RIGHT-NET). Investigators, Co-Principal Investigators: Eduardo Bossone (A. Cardarelli Hospital, Naples, Italy), Luna Gargani (Institute of Clinical Physiology, CNR, Pisa, Italy), Robert Naeije (Free University of Brussels, Brussels, Belgium). Study Coordinator: Francesco Ferrara (Cava de’ Tirreni and Amalfi Coast Division of Cardiology, University Hospital, Salerno, Italy). Co-Investigators: William F. Armstrong, Theodore John Kolas (University of Michigan, Ann Arbor, MI, USA); Eduardo Bossone, Roberto Annunziata, Valentina Capone, Salvatore Chianese, Rosangela Cocchia, Marianna Conti, Ciro Mauro, Chiara Sepe (A. Cardarelli Hospital, Naples, Italy); Filippo Cademartiri, Rossana Castaldo, Monica Francesze, Brigida Ranieri, Andrea Salzano (IRCCS SDN, Diagnostic and Nuclear Research Institute, Naples, Italy); Rodolfo Citro, Michele Bellino, Rossella Benvenuta, Giuseppe Iuliano, Ilaria Radano (University Hospital of Salerno, Salerno, Italy); Antonio Cittadini, Roberta D’Assante, Nicola Ferrara, Alberto Marra, Renato Maramaldi, Teresa Saltalamacchia, Salvatore Rega (Department of Translational Medical Sciences, “Federico II” University of Naples, Naples, Italy); Michele D’Alto, Paola Argiento (University of Campania “Luigi Vanvitelli”, Naples, Italy); Antonello D’Andrea (Umberto I Hospital Nocera Inferiore, Italy); Santo Dellegrottaglie (Ospedale Medico-Chirurgico Accreditato Villa dei Fiori, Acerra-Naples, Italy); Nicola De Luca, Raffaele Izzo, Francesca Rozza, Ciro Santoro (Hypertension Research Center, University Federico II of Naples, Italy); Giovanni Di Salvo (University of Padova, Italy; Imperial College, London, UK); Francesco Ferrara, Marisa Malinconico, Valentina Russo (Cava de’ Tirreni and Amalfi Coast Hospital, University Hospital of Salerno, Italy); Luna Gargani, Matteo Mazzola, Marco Raciti (Institute of Clinical Physiology, CNR, Pisa, Italy); Stefano Ghio, Stefania Guida (I.R.C.C.S. Policlinico San Matteo, Pavia, Italy); Ekkerard Grunig, Christina A. Eichstaedt (Heidelberg University Hospital, Germany); Marco Guazzi, Francesco Bandera, Valeria Labate (IRCCS Policlinico San Donato, University of Milan, Milan, Italy); André La Gerche (Baker Heart and Diabetes Institute, Melbourne, Australia); Giuseppe Limongelli, Giuseppe Pacileo, Marina Verri (University of Campania “Luigi Vanvitelli”, Naples, Italy); Jaroslav D. Kasprzak, Karina Wierzbowska-Drabik (Bieganski Hospital, Medical University of Lodz Poland); Gabor Kovacs, Philipp Douschan (Medical University of Graz, Graz, Austria); Antonella Moreo, Francesca Casadei, Benedetta De Chiara, (Niguarda Hospital, Milan, Italy); Robert Naeije (Free University of Brussels, Brussels, Belgium); Ellen Ostenfeld (Lund University, Skåne University Hospital, Sweden); Gianni Pedrizzetti (Department of Engineering and Architecture, University of Trieste); Francesco Pieri, Alberto Moggi-Pignone, Fabio Mori (Azienda Ospedaliero-Universitaria Careggi, Florence, Italy); Lorenza Pratali (Institute of Clinical Physiology, CNR, Pisa, Italy); Nicola Pugliese (Department of Clinical and Experimental Medicine, University of Pisa, Italy); Lawrence Rudski (Azrieli Heart Center and Center for Pulmonary Vascular Diseases, Jewish General Hospital, McGill University, Montreal, Quebec, Canada); Rajan Saggar (UCLA Medical Center, Los Angeles, CA, USA); Walter Serra (University Hospital of Parma, Italy); Anna Agnese Stanziali, Rossella D’Angelo, Lorena Gallotta (Department of Respiratory Disease, Federico II University, Monaldi Hospital, Naples, Italy); István Szabó (University of Medicine and Pharmacy of Târgu Mureș, Târgu Mures, Romania); Albert Varga, Gergely Agoston, (University of Szeged, Szeged, Hungary); Damien Voilliot (Centre Hospitalier Lunéville, France); Olga Vriz, Domenico Galzerano (Heart Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia).

**Conflicts of Interest:** Authors are not directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work.

**Disclosures:** The authors have no relevant financial or non-financial interest to disclose.

**References**

1. Drazner, M.H. The progression of hypertensive heart disease. *Circulation* 2011, 123, 327–334. [CrossRef] [PubMed]
2. Reddy, Y.N.V.; Borlaug, B.A. Heart failure with preserved ejection fraction. *Curr. Probl. Cardiol.* 2016, 41, 145–188. [CrossRef]
3. McDonagh, T.; Metra, M. ESC scientific document group, 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur. Heart J.* 2021, 42, 3599–3726. [PubMed]
4. Williams, B.; Mancia, G. ESC scientific document group, 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur. Heart J.*, 2018, 39, 3021–3014. [CrossRef] [PubMed]

5. Burgess, M.J.; Jenkins, C.; Sharman, J.E.; Marwick, T.H. Diastolic stress echocardiography: Hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise. *J. Am. Coll. Cardiol.*, 2006, 47, 1891–1900. [CrossRef] [PubMed]

6. Chen, Z.-W.; Huang, C.-Y. Stress echocardiography-derived E/e' predicts abnormal exercise hemodynamics in heart failure with preserved ejection fraction. *Front. Physiol.*, 2019, 10, 1470. [CrossRef]

7. Ferrara, F.; Gargani, L. The right heart international network (RIGHT-NET): Rationale, objectives, methodology, and clinical implications. *Heart Fail. Clin.*, 2018, 14, 443–465. [CrossRef]

8. Ferrara, F.; Gargani, L. A multicentric quality-control study of exercise Doppler echocardiography of the right heart and the pulmonary circulation. The RIGHT heart international NETwork (RIGHT-NET). *Cardiovasc. Ultrasound*, 2021, 19, 9. [CrossRef]

9. Ferrara, F.; Gargani, L. Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: The RIGHT heart international NETwork (RIGHT-NET). *Int. J. Cardiovasc. Imaging*, 2021, 37, 2151–2167. [CrossRef]

10. Ferrara, F.; Rudski, L.G.; Vriz, O.; Gargani, L.; Afifalo, J.; D’Andrea, A.; D’Alto, M.; Marra, A.M.; Acri, E.; Stanzioia, A.A.; et al. Physiologic correlates of tricuspid annular plane systolic excursion in 1168 healthy subjects. *Int. J. Cardiof.*, 2016, 223, 736–743. [CrossRef]

11. Vriz, O.; Pirisi, M.; Habib, E.; Galzerano, D.; Fadel, B.; Antonini-Canterin, F.; Veldtman, G.; Bossone, E. Age related structural and functional changes in left ventricular performance in healthy subjects: A 2D echocardiographic study. *Int. J. Cardiovasc. Imaging*, 2019, 35, 2037–2047. [CrossRef]

12. Vriz, O.; Pirisi, M.; Bosson, E.; ElMula, F.E.M.F.; Palatini, P.; Naeije, R. Right ventricular–pulmonary arterial uncoupling in mild-to-moderate systemic hypertension. *J. Hypertens.*, 2020, 38, 274–281. [CrossRef]

13. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afifalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J. Am. Soc. Echocardiogr.*, 2015, 28, 1–39.e14. [CrossRef]

14. Rudski, L.G.; Lai, W.W. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J. Am. Soc. Echocardiogr. Off Publ. Am. Soc. Echocardiogr.*, 2010, 23, 685–713; quiz 786–788. [CrossRef]

15. Nagueh, S.F.; Smiseth, O.A.; Appleton, C.P.; Byrd, B.F.; Dokainish, H.; Edvardsen, T.; Flachskampf, F.A.; Gillebert, T.; Klein, A.L.; Lancellotti, P.; et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J. Am. Soc. Echocardiogr. Off Publ. Am. Soc. Echocardiogr.*, 2016, 29, 277–314. [CrossRef]

16. Yock, P.G.; Popp, R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. *Circulation*, 1984, 70, 657–662. [CrossRef] [PubMed]

17. Chemla, D.; Castelain, V.; Humbert, M.; Hébert, J.L.; Simonneau, G.; Lecerfartent, Y.; Hervé, P. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. *Chesnt 2004*, 126, 1313–1317. [CrossRef] [PubMed]

18. Guazzi, M.; Bandera, F. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: An index of right ventricular contractile function and prognosis. *Am. J. Physiol. Heart Circ. Physiol.*, 2013, 305, H1373–H1381. [CrossRef]

19. Lancellotti, P.; Pellikka, P.A.; Budts, W.; Chaudhry, F.A.; Donal, E.; Dulgheru, R.; Edvardsen, T.; Garbi, M.; Hål, W.; KaneG, C.; et al. The clinical use of stress echocardiography in non-ischaemic heart disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J. Am. Soc. Echocardiogr.*, 2017, 30, 101–138. [CrossRef] [PubMed]

20. Sicari, R.; Nihoyannopoulos, P. Stress echocardiography expert consensus statement—Executive summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). *Eur. Heart J.*, 2009, 30, 278–289. [CrossRef]

21. Knuuti, J.; Wijns, W. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur. Heart J.*, 2020, 41, 407–477. [CrossRef]

22. Garbi, M.; Chambers, J.; Vannan, M.A.; Lancellotti, P. Valve stress echocardiography. *JACC Cardiovasc. Imaging*, 2015, 8, 724–736. [CrossRef]

23. Pieske, B.; Tschöpe, C. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur. Heart J.*, 2019, 40, 3297–3317. [CrossRef]

24. Kasner, M.; Sinning, D.; Lober, J.; Post, H.; Fraser, A.G.; Pieske, B.; Burkhoff, D.; Tschöpe, C. Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction. *ESC Heart Fail.*, 2015, 2, 121–132. [CrossRef] [PubMed]
25. Obokata, M.; Kane, G. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: A simultaneous invasive-echocardiographic study. *Circulation* **2017**, *135*, 825–838. [CrossRef] [PubMed]

26. Kovacs, G.; Herve, P. An official European Respiratory Society statement: Pulmonary haemodynamics during exercise. *Eur. Respir. J*. **2017**, *50*, 1708578. [CrossRef] [PubMed]

27. Rudski, L.; Gargani, L.; Armstrong, W.F.; Lancellotti, P.; Lester, S.J.; Grünig, E.; D’Alto, M.; Aneg, M.Â.; Ferrara, F.; Saggar, R.; et al. Stressing the cardiopulmonary vascular system: The role of echocardiography. *J. Am. Soc. Echocardiogr.* **2018**, *31*, 527–550.e11.

28. Lewis, G.D.; Bossone, E. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. *Circulation* **2013**, *128*, 1470–1479. [CrossRef]

29. Naeije, M.; Saggar, R. Exercise-induced pulmonary hypertension: Translating pathophysiological concepts into clinical practice. *Chest* **2018**, *154*, 10–15. [CrossRef]

30. Argiento, P.; Chesler, N. Exercise stress echocardiography of the pulmonary circulation and right ventricular-arterial coupling in healthy adolescents. *Eur. Heart J.* **2017**, *69*, 1718–1734. [CrossRef]

31. Grünig, E.; MacKenzie, A.; Peacock, A.J.; Eichstaedt, C.A.; Benjamin, N.; Nechwald, R.; Ulrich, S.; Saxer, S.; Bussotti, S.; Sommaruga, M.; et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: Results from a large European multicentre randomized controlled trial. *Eur. Heart J.* **2021**, *42*, 2284–2295. [CrossRef]

32. Pugliese, N.R.; Mazzola, M. Hemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test. *Eur. J. Heart Fail.* **2020**, *22*, 458–468. [CrossRef] [PubMed]

33. Argiento, P.; Chesler, N. Exercise stress echocardiography for the study of the pulmonary circulation. *Eur. Respir. J.* **2010**, *35*, 1273–1278. [CrossRef]

34. Argiento, P.; Vanderpool, R.R. Exercise stress echocardiography of the pulmonary circulation: Limits of normal and sex differences. *Chest* **2012**, *142*, 1158–1165. [CrossRef]

35. Bossone, E.; Rubenfire, M.; Bach, D.S.; Ricciardi, M.; Armstrong, W.F. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: Implications for the diagnosis of pulmonary hypertension. *J. Am. Coll. Cardiol.* **1999**, *33*, 1662–1666. [CrossRef]

36. Forton, K.; Motoji, Y.; Caravita, S.; Faoro, V.; Naeije, R. Exercise stress echocardiography of the pulmonary circulation and right ventricular-arterial coupling in healthy adolescents. *Eur. Heart J. Cardiovasc. Imaging* **2021**, *22*, 688–694. [CrossRef]

37. Lam, C.S.P.; Borlaug, B.A. Age-Associated increases in pulmonary artery systolic pressure in the general population. *Circulation* **2009**, *119*, 2663–2670. [CrossRef] [PubMed]

38. Kovacs, G.; Berghold, A.; Scheidl, S.; Olschewski, H. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review. *Eur. Respir. J.* **2009**, *34*, 888–894. [CrossRef]

39. Vriz, O.; Feldman, G. Age-changes in right ventricular function-pulmonary circulation coupling: From pediatric to adult stage in 1899 healthy subjects. The RIGHT Heart International NETwork (RIGHT-NET). *Int. J. Cardiovasc. Imaging* **2021**, *37*, 3399–3411. [CrossRef]

40. Vriz, O.; Argiento, P.; D’Alto, M.; Ferrara, F.; Vanderpool, R.; Naeije, R.; Bossone, E. Increased pulmonary vascular resistance in early stage systemic hypertension: A resting and exercise stress echocardiography study. *Can. J. Cardiol.* **2015**, *31*, 537–543. [CrossRef]

41. Shah, A.M.; Claggett, B. Contemporary assessment of left ventricular diastolic function in older adults: The atherosclerosis risk in communities study. *Circulation* **2017**, *135*, 426–439. [CrossRef] [PubMed]

42. Donal, E.; Galli, E.; Fraser, A.G. Non-invasive estimation of left heart filling pressures: Another nail in the coffin for E/e’? *Eur. J. Heart Fail.* **2017**, *19*, 1661–1663. [CrossRef] [PubMed]

43. Wachtler, R.; Schmidt-Schweda, S.; Westermann, D.; Post, H.; Edelmann, F.; Kasner, M.; Lüers, C.; Steen dik, P.; Hasenfuß, G.; Tschöpe, C.; et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. *Eur. Heart J.* **2009**, *30*, 3027–3036. [CrossRef] [PubMed]

44. Dorfs, S.; Zeh, W. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. *Eur. Heart J.* **2014**, *35*, 3103–3112. [CrossRef]

45. Shim, C.Y.; Kim, S.-A.; Choi, D.; Yang, W.-I.; Kim, J.-M.; Moon, S.-H.; Lee, H.-J.; Park, S.; Choi, E.-Y.; Chung, N.; et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: Implication of an increase in left ventricular filling pressure during exercise. *Heart Br. Card. Soc.* **2011**, *97*, 1417–1424. [CrossRef]

46. Schmeisser, A.; Rauwolf, T. Pressure–volume loop validation of TAPSE/PASP for right ventricular arterial coupling in heart failure with pulmonary hypertension. *Eur. Heart J. Cardiovasc. Imaging* **2021**, *22*, 168–176. [CrossRef]